Tag - SOR-C13

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...

December 12, 2017

Feature

In conversation with Paul Gunn

By Len Zehr As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by...

April 26, 2016

Tag - SOR-C13

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

In conversation with Paul Gunn

General

More